Generation Bio Co
GBIO5.750USD
-0.230-3.85%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.87MMarket Cap
LossP/E TTM
More Details of Generation Bio Co Company
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
Company Info
Ticker SymbolGBIO
Company nameGeneration Bio Co
IPO dateJun 12, 2020
CEODr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Number of employees115
Security typeOrdinary Share
Fiscal year-endJun 12
Address301 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone18575295908
Websitehttps://generationbio.com/
Ticker SymbolGBIO
IPO dateJun 12, 2020
CEODr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
185.48K
+0.20%
Dr. Anthony G. Quinn, M.D., Ph.D.
Dr. Anthony G. Quinn, M.D., Ph.D.
Independent Director
Independent Director
37.21K
--
Mr. Gustav A. Christensen
Mr. Gustav A. Christensen
Independent Director
Independent Director
13.14K
--
Dr. Phillip Samayoa, Ph.D.
Dr. Phillip Samayoa, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
12.93K
+0.63%
Ms. Yalonda Howze, J.D.
Ms. Yalonda Howze, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
6.70K
+3.67%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
4.75K
--
Ms. Dannielle Appelhans
Ms. Dannielle Appelhans
Independent Director
Independent Director
2.00K
+150.00%
Mr. Kevin John Conway
Mr. Kevin John Conway
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
1.83K
+2.35%
Mr. Ronald Harold Wilfred (Ron) Cooper
Mr. Ronald Harold Wilfred (Ron) Cooper
Independent Director
Independent Director
950.00
--
Dr. Jeffrey M. (Jeff) Jonas, M.D.
Dr. Jeffrey M. (Jeff) Jonas, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
185.48K
+0.20%
Dr. Anthony G. Quinn, M.D., Ph.D.
Dr. Anthony G. Quinn, M.D., Ph.D.
Independent Director
Independent Director
37.21K
--
Mr. Gustav A. Christensen
Mr. Gustav A. Christensen
Independent Director
Independent Director
13.14K
--
Dr. Phillip Samayoa, Ph.D.
Dr. Phillip Samayoa, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
12.93K
+0.63%
Ms. Yalonda Howze, J.D.
Ms. Yalonda Howze, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
6.70K
+3.67%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
4.75K
--
Revenue Breakdown
FY2024
FY2023
No Data
By RegionUSD
Name
Revenue
Proportion
United States
19.89M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Associates, Inc.
12.32%
Atlas Venture
12.29%
Modernatx Inc
8.70%
Invus Public Equities Advisors, LLC
4.41%
Renaissance Technologies LLC
3.83%
Other
58.45%
Shareholders
Shareholders
Proportion
T. Rowe Price Associates, Inc.
12.32%
Atlas Venture
12.29%
Modernatx Inc
8.70%
Invus Public Equities Advisors, LLC
4.41%
Renaissance Technologies LLC
3.83%
Other
58.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.15%
Venture Capital
12.29%
Hedge Fund
9.45%
Corporation
8.70%
Individual Investor
5.61%
Investment Advisor/Hedge Fund
5.08%
Research Firm
4.23%
Family Office
0.10%
Other
23.39%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
205
5.68M
84.67%
-1.87M
2025Q1
216
58.42M
87.25%
-16.87M
2024Q4
239
64.26M
96.22%
-10.38M
2024Q3
252
65.74M
98.51%
-9.46M
2024Q2
257
65.96M
99.11%
-9.63M
2024Q1
256
65.28M
99.25%
-2.56M
2023Q4
262
62.66M
95.79%
-3.14M
2023Q3
260
66.58M
101.93%
-550.54K
2023Q2
272
66.62M
102.34%
-297.13K
2023Q1
283
66.66M
111.77%
+650.55K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Associates, Inc.
8.88M
13.25%
-217.22K
-2.39%
Mar 31, 2025
Atlas Venture
8.28M
12.35%
--
--
Mar 31, 2025
Modernatx Inc
5.86M
8.74%
--
--
Apr 07, 2025
Invus Public Equities Advisors, LLC
2.97M
4.43%
-13.81K
-0.46%
Mar 31, 2025
Renaissance Technologies LLC
1.88M
2.81%
+917.71K
+95.30%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.75M
7.09%
+126.37K
+2.73%
Mar 31, 2025
The Vanguard Group, Inc.
2.62M
3.91%
-22.29K
-0.84%
Mar 31, 2025
Baker Bros. Advisors LP
1.94M
2.9%
--
--
Mar 31, 2025
McDonough (Cameron Geoffrey)
1.85M
2.76%
+15.31K
+0.83%
Apr 15, 2025
Acadian Asset Management LLC
1.16M
1.73%
+407.84K
+54.29%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Global X Russell 2000 Covered Call ETF
0%
Fidelity Blue Chip Growth ETF
0%
Avantis US Equity ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Fidelity Blue Chip Growth ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
